Lichen planopilaris (LPP) is the most common primary cicatricial alopecia. It is a chronic, progressive inflammatory disorder characterised by a presence of T-cell lymphocytes at the dermal-epidermal junction. Managing LPP remains challenging due to the limited availability of high-quality data and lack of specific treatment guidelines. Recently the novel therapeutic agents have been emerging for the treatment of chronic inflammatory skin diseases: biologics and Janus kinase inhibitors. This article presents a comprehensive review of the literature regarding the treatment of LPP with a focus on novel therapeutical approaches – oral minoxidil, Janus kinase inhibitors, and biologics. Randomised clinical trials, cohort studies as well as case reports were included in this review. JAK inhibitors appear to be an effective therapeutic agents for LPP. Furthermore, interleukin 17 inhibition seems to be a promising emerging therapy as well. Further clinical trials are required to establish their position in therapeutic indications and guidelines for LPP.